Showing results (291-300 of 336) with videos related to
Sort By:
Pageof 34
Cancer Research Communications|October 11, 2024
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung CancerHidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLCAtsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, et al.Lancet (London, England)|April 24, 2022
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trialHisashi Saji, Morihito Okada, Masahiro Tsuboi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2020
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2015
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung CancerYasuo Iwamoto, Tetsuya Mitsudomi, Kazuko Sakai, et al.International Journal of Clinical Oncology|August 31, 2021
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101)Masafumi Yamaguchi, Hirohito Tada, Tetsuya Mitsudomi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical TrialsMatthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, et al.JTO Clinical and Research Reports|April 10, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)Satoru Miura, Makoto Nishio, Hiroaki Akamatsu, et al.The Lancet. Oncology|December 22, 2009
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialTetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, et al.Pageof 34